Related Experiment Videos
Drug therapy of sustained ventricular tachyarrhythmias. Is there still a role?
1Division of Cardiology, University of Calgary, Alberta, Canada.
Abstract:
This article provides a review of the risks faced by patients with sustained ventricular tachycardia (VT) or ventricular fibrillation (VF) in the absence of a reversible or transient cause so that the goals of therapy can be clearly defined. The therapeutic approaches that have been proposed to achieve these goals are outlined and evidence comparing these various approaches to therapy is then summarized in order to propose an algorithm for the optimal use of antiarrhythmic drug therapies as primary therapy for selected VT/VF patients. Options for the ancillary uses of antiarrhythmic drug therapies in ICD patients are considered.
Insights
This review clarifies risks for sustained ventricular tachycardia (VT) and ventricular fibrillation (VF) patients. It proposes an algorithm for optimal antiarrhythmic drug therapy, including use with implantable cardioverter-defibrillators (ICDs).
Area of Science:
- Cardiology
- Electrophysiology
- Pharmacology
Background:
- Sustained ventricular tachycardia (VT) and ventricular fibrillation (VF) pose significant risks, especially when no reversible cause is identified.
- Defining clear therapeutic goals is crucial for managing these life-threatening arrhythmias.
Purpose of the Study:
- To review the risks associated with sustained VT/VF in the absence of reversible causes.
- To outline proposed therapeutic approaches and summarize evidence for their efficacy.
- To propose an algorithm for the optimal use of antiarrhythmic drugs in selected VT/VF patients and consider their use in ICD patients.
Main Methods:
- Literature review of risks, therapeutic approaches, and comparative evidence for antiarrhythmic drug therapies.
- Synthesis of evidence to develop a treatment algorithm.
Main Results:
- Identification of key risks in patients with sustained VT/VF.
- Comparison of various therapeutic strategies, including antiarrhythmic drugs.
- Development of an evidence-based algorithm for primary and ancillary antiarrhythmic drug therapy.
Conclusions:
- Optimizing antiarrhythmic drug therapy requires a clear understanding of risks and evidence-based treatment selection.
- An algorithm can guide the primary use of antiarrhythmic drugs for selected VT/VF patients.
- Antiarrhythmic drugs have defined ancillary roles in patients with implantable cardioverter-defibrillators (ICDs).